SecBot SecBot
SECBOTREPLAY Home › Report › INM

INM · InMed announced a 1-for-10 share consolidation conditional on…

InMed Pharmaceuticals Inc. · 425 filed Nov 2, 2026 at 16:56 ET

At the news

NEUTRALIMPACT 3/10

425 filed Nov 2, 2026 at 16:56 ET

InMed announced a 1-for-10 share consolidation conditional on shareholder approval of three proposals at the November 4, 2026 meeting. The consolidation is a procedural step to facilitate the pending merger with Mentari Therapeutics, reducing outstanding shares from 5,493,735 to approximately 549,374. No changes to deal terms or financials were disclosed.

  • InMed announced a 1-for-10 share consolidation, reducing outstanding shares from 5,493,735 to approximately 549,374.
  • The consolidation is conditional on shareholder approval of the Nasdaq Share Issuance Proposal, Return of Capital Proposal, and Redomestication Proposal at the November 4, 2026 meeting.
  • The consolidation is expected to be completed after market close on November 4, 2026, with post-consolidation shares trading on Nasdaq on November 5, 2026.
  • This is a procedural step in the previously announced merger with Mentari Therapeutics, with no changes to deal terms or financials.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access